BrightSpring Health Services, Inc. (BTSG)
NASDAQ (NGS) NASDAQ (NGS) Primary 
BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026?
BrightSpring's shares surge 67.3% year to date, fueled by strong pharmacy and provider growth, improving profitability and a brighter 2026 outlook.
BrightSpring: Margins Keep Improving While Expanding Its Pharmacy Footprint
I believe BrightSpring Health Services' pharmacy and home-care businesses have a few ways to monetize their sizeable revenues into higher EBITDA over time. BTSG's new oncology distribution wins also grow their addressable market, which is why drug adoption is vital going forward. BTSG's recently acquired home-health branches also have interesting potential as their integration progresses.
BrightSpring Health Targets Growth Through Specialty Pharmacy, M&A and AI
BrightSpring Health Services NASDAQ: BTSG outlined its growth strategy across pharmacy and provider services at the Bernstein healthcare services conference, emphasizing specialty pharmacy expansion, home health acquisitions, technology investments and opportunities to integrate services for complex patients.
BTSG Faces $200M IRA Hit but Efficiency May Protect Profitability
BTSG faces a $200M 2026 IRA revenue headwind in Home Pharmacy, but efficiency gains and technology are helping protect profitability.
BrightSpring Health Services, Inc. (BTSG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BrightSpring Health Services, Inc. (BTSG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now
BTSG's specialty pharmacy, infusion and home-based care expansion support growth, while IRA and execution risks may put pressure on near-term margins.
BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell?
BrightSpring Health Services has surged 54% YTD on specialty pharmacy, infusion and EBITDA growth, but premium valuation and policy headwinds remain.
BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?
BrightSpring Health Services' Specialty and Infusion sales rose 30%, backed by LDD growth, new launches and expansion into rare therapies.
BrightSpring Health Services: 44% Ebitda Growth Is Hard To Ignore
BrightSpring Health Services is rated buy, driven by rapid profitability growth, expanding Provider Services, and reduced financial leverage. In Q2, revenue grew 23% and adjusted EBITDA surged 44%, with management raising 2026 guidance for both revenue and EBITDA. BTSG's premium 34.38x FY1 P/E is justified by strong EBITDA growth and a forward PEG of 0.73x, with multiples declining to 22.19x by FY3.
Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth?
BrightSpring Health Services is gaining acute infusion share with 20%+ volume growth, targeting 12-15 new states in a $20 billion market.
New Strong Buy Stocks for August 26th
BTSG, OPHC, HRTG, UMC and MTG have been added to the Zacks Rank #1 (Strong Buy) List on August 26th, 2026.
Sandisk & 2 Profitable Stocks to Buy Now for Explosive Upside
Sandisk, Celestica and BrightSpring rank among profitable stocks, with strong net income ratios and earnings growth supporting upside.
